Xtandi 40 MG tablet 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FJFS6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units). This firm fixed-price delivery order, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award utilizes DMS Pharmaceutical Group's single-award Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to support Department of Defense pharmaceutical supply requirements. This parent contract, designated SPE2DR and valued at $499,999,999, was awarded in November 2025 with a completion date of December 31, 2036, and includes a 30-month base period with three 30-month option periods.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military healthcare supply chain, with recent delivery orders spanning diverse pharmaceutical categories including oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals. The contractor supplies military healthcare facilities worldwide with both branded and generic prescription drugs, over-the-counter medications, and medical consumables. All identified awards have been funded by the Defense Logistics Agency with no identified subcontractor relationships, positioning DMS Pharmaceutical Group as a primary distributor for recurring Department of Defense medical supply needs globally.
Quick answers
Who was awarded contract SPE2DR26FJFS6?
SPE2DR26FJFS6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FJFS6 worth?
The government has obligated $4,255 on SPE2DR26FJFS6.
Is contract SPE2DR26FJFS6 an order under another contract?
Yes. SPE2DR26FJFS6 is a delivery order under SPE2DR25D9157, an indefinite delivery contract.
Was contract SPE2DR26FJFS6 competed?
The extent of competition for SPE2DR26FJFS6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award